SB-509
/ Biogen, Sangamo Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 25, 2011
Sangamo BioSciences reports third quarter 2011 financial results
(PRNewswire)
- Sangamo's P2b Trial (SB-509-901) in subjects with moderately severe diabetic neuropathy did not meet key endpoints; Based on the data, the company announced that it has discontinued further development of SB-509
Discontinued • Pain
January 10, 2011
Sangamo BioSciences announces completion of enrollment of phase 2b clinical trial in diabetic neuropathy
(PRNewswire)
-
Company expects to have efficacy data from this study in H1 ’11;
Anticipated launch • Pain
April 10, 2019
"It’s a great day for #Oklahoma patients! #SB509 has passed the Oklahoma House! Thank you @chad4ok @Conley4House @RepSheilaDills @MBlancett @CyndiMunson85 @MickeyDollens for supporting #steptherapy reform. On to the Governor’s desk! #oklege"
(@NPF)
Clinical
March 20, 2019
"Thank you @tulsaworld for capturing the importance of #steptherapy reform and supporting #SB509 sponsored by Tulsa Sen. @CoachDaveRader & #HB2638 by Rep. @CyndiMunson85 @jonechols as commonsense protections for Oklahomans. https://t.co/aKLqX65WHG #NPFadvocacy #OKlege"
(@NPF)
1 to 4
Of
4
Go to page
1